

Moshe Weinstein

Moshe Weinstein, MBA, is CEO of Moebius Medical, a clinical stage biotechnology company developing a novel pain relief treatment for osteoarthritis. Under Moshe's leadership, Moebius Medical signed an exclusive license agreement with Sun Pharmaceuticals in December 2016, and the two companies are now jointly developing Moebius's lead product MM-II. Moshe brings with him over 17 years of global business experience. Prior to returning to Israel and joining Moebius in 2015, Moshe spent 7 years at Novartis in the US and Latin America where he held positions of increasing responsibility in business development & licensing, sales, marketing and commercial management. Prior to Novartis, Moshe served as a consultant for PricewaterhouseCoopers, with a focus on supporting early stage healthcare companies to develop business plans and raise capital. Moshe earned an MBA from INSEAD, and has a bachelors in business & management from Yeshiva University in New York.